by Fred Dumais | Nov 22, 2022 | News Release
Valeo’s President and Chief Operating Officer steps down and will continue as special advisor and member of the Board of Directors MONTREAL, QUEBEC , November 21, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian...
by Fred Dumais | Nov 15, 2022 | News Release
Q4-2022 revenue guidance raised to a record $12.5M – $13.0MFiscal 2022 revenue guidance increased to a record $27.5M – $28.0M MONTREAL, QUEBEC , November 15, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the “Company”), a Canadian...
by Fred Dumais | Sep 14, 2022 | News Release
In a Phase 3 cinical study interim analysis, sabizabulin showed a 55.2% reduction in deaths compared to placebo in hospitalized adult patients with moderate-severe COVID-19 who are at high risk for ARDSSabizabulin also showed significant reduction of days in ICU, days...
by Fred Dumais | Sep 13, 2022 | News Release
Record revenues of $6.1 million in Q3-22, a 27% increase over Q2-22 Record Gross Margins of $2.2 million in Q3-22, up 34% over Q2-22Record YTD-22 revenues of $15.1 million, up 48% over YTD 2021Q4-22 projected revenues to exceed $11 millionXIIDRA®, SIMBRINZA® and...
by Fred Dumais | Sep 9, 2022 | News Release
MONTREAL, QUEBEC , September 9, 2022 – Valeo Pharma Inc. (TSX:VPH, OTCQB: VPHIF, FSE:VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today that it will report its financial results and highlights for the third quarter ended July 31, 2022...
by Fred Dumais | Aug 30, 2022 | News Release
Kyle Steiger appointed Senior Vice-President and Chief Commercial OfficerJean-François Fournier appointed new Business Unit Head – Ophthalmology MONTREAL, QUEBEC, August 30, 2022 – Valeo Pharma Inc. (TSX: VPH, OTCQB: VPHIF, FSE: VP2) (“Valeo” or the...
